Dynavax Technologies Corporation (0IDA.L)
USD 12.75
(-1.43%)
USD 12.75
(-1.43%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 997.09 Million USD | 1.14% |
| 2022 | 985.85 Million USD | -5.14% |
| 2021 | 1.03 Billion USD | 194.18% |
| 2020 | 353.27 Million USD | 26.59% |
| 2019 | 279.06 Million USD | 32.33% |
| 2018 | 210.88 Million USD | -3.61% |
| 2017 | 218.78 Million USD | 99.48% |
| 2016 | 109.68 Million USD | -49.37% |
| 2015 | 216.63 Million USD | 56.65% |
| 2014 | 138.29 Million USD | -32.42% |
| 2013 | 204.62 Million USD | 46.42% |
| 2012 | 139.75 Million USD | 4.21% |
| 2011 | 134.1 Million USD | 59.17% |
| 2010 | 84.24 Million USD | 66.93% |
| 2009 | 50.47 Million USD | -44.31% |
| 2008 | 90.62 Million USD | -24.76% |
| 2007 | 120.44 Million USD | 17.07% |
| 2006 | 102.89 Million USD | 28.46% |
| 2005 | 80.09 Million USD | 8.75% |
| 2004 | 73.64 Million USD | 133.17% |
| 2003 | 31.58 Million USD | 0.34% |
| 2002 | 31.47 Million USD | 108.23% |
| 2001 | 15.11 Million USD | -48.91% |
| 2000 | 29.59 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 986.56 Million USD | -1.06% |
| 2024 Q2 | 1.01 Billion USD | 3.02% |
| 2023 Q3 | 972.93 Million USD | 3.9% |
| 2023 Q2 | 936.43 Million USD | -3.45% |
| 2023 Q1 | 969.92 Million USD | -1.62% |
| 2023 Q4 | 997.09 Million USD | 2.48% |
| 2023 FY | 997.09 Million USD | 1.14% |
| 2022 Q4 | 985.85 Million USD | -1.35% |
| 2022 FY | 985.85 Million USD | -5.14% |
| 2022 Q2 | 1.02 Billion USD | 1.39% |
| 2022 Q3 | 999.33 Million USD | -2.31% |
| 2022 Q1 | 1 Billion USD | -2.91% |
| 2021 Q4 | 1.03 Billion USD | 13.0% |
| 2021 FY | 1.03 Billion USD | 194.18% |
| 2021 Q2 | 647.9 Million USD | 32.19% |
| 2021 Q1 | 490.11 Million USD | 38.74% |
| 2021 Q3 | 919.71 Million USD | 41.95% |
| 2020 FY | 353.27 Million USD | 26.59% |
| 2020 Q2 | 329.31 Million USD | 27.02% |
| 2020 Q3 | 353.39 Million USD | 7.31% |
| 2020 Q4 | 353.27 Million USD | -0.03% |
| 2020 Q1 | 259.25 Million USD | -7.1% |
| 2019 Q3 | 301.01 Million USD | 12.71% |
| 2019 Q2 | 267.08 Million USD | -9.95% |
| 2019 Q1 | 296.6 Million USD | 40.65% |
| 2019 FY | 279.06 Million USD | 32.33% |
| 2019 Q4 | 279.06 Million USD | -7.29% |
| 2018 FY | 210.88 Million USD | -3.61% |
| 2018 Q1 | 295.33 Million USD | 34.99% |
| 2018 Q2 | 263.86 Million USD | -10.66% |
| 2018 Q4 | 210.88 Million USD | -10.79% |
| 2018 Q3 | 236.38 Million USD | -10.41% |
| 2017 Q4 | 218.78 Million USD | 0.44% |
| 2017 FY | 218.78 Million USD | 99.48% |
| 2017 Q3 | 217.82 Million USD | 43.34% |
| 2017 Q2 | 151.96 Million USD | 37.99% |
| 2017 Q1 | 110.13 Million USD | 0.41% |
| 2016 Q3 | 139.29 Million USD | -16.89% |
| 2016 Q4 | 109.68 Million USD | -21.26% |
| 2016 FY | 109.68 Million USD | -49.37% |
| 2016 Q2 | 167.61 Million USD | -11.62% |
| 2016 Q1 | 189.64 Million USD | -12.46% |
| 2015 Q3 | 238.9 Million USD | 118.19% |
| 2015 Q4 | 216.63 Million USD | -9.32% |
| 2015 FY | 216.63 Million USD | 56.65% |
| 2015 Q1 | 112.16 Million USD | -18.89% |
| 2015 Q2 | 109.49 Million USD | -2.38% |
| 2014 Q1 | 193.58 Million USD | -5.39% |
| 2014 FY | 138.29 Million USD | -32.42% |
| 2014 Q4 | 138.29 Million USD | -5.86% |
| 2014 Q3 | 146.89 Million USD | -15.32% |
| 2014 Q2 | 173.46 Million USD | -10.39% |
| 2013 FY | 204.62 Million USD | 46.42% |
| 2013 Q1 | 119.62 Million USD | -14.4% |
| 2013 Q2 | 104.01 Million USD | -13.05% |
| 2013 Q3 | 91.69 Million USD | -11.84% |
| 2013 Q4 | 204.62 Million USD | 123.15% |
| 2012 FY | 139.75 Million USD | 4.21% |
| 2012 Q2 | 175.89 Million USD | 45.76% |
| 2012 Q3 | 164.82 Million USD | -6.3% |
| 2012 Q4 | 139.75 Million USD | -15.21% |
| 2012 Q1 | 120.67 Million USD | -10.01% |
| 2011 FY | 134.1 Million USD | 59.17% |
| 2011 Q4 | 134.1 Million USD | 107.21% |
| 2011 Q2 | 74.43 Million USD | 13.62% |
| 2011 Q1 | 65.5 Million USD | -22.25% |
| 2011 Q3 | 64.71 Million USD | -13.05% |
| 2010 Q1 | 44.28 Million USD | -12.26% |
| 2010 Q4 | 84.24 Million USD | 36.35% |
| 2010 Q3 | 61.79 Million USD | -13.8% |
| 2010 Q2 | 71.67 Million USD | 61.86% |
| 2010 FY | 84.24 Million USD | 66.93% |
| 2009 Q1 | 78.14 Million USD | -13.77% |
| 2009 FY | 50.47 Million USD | -44.31% |
| 2009 Q4 | 50.47 Million USD | -18.13% |
| 2009 Q3 | 61.64 Million USD | -10.85% |
| 2009 Q2 | 69.14 Million USD | -11.51% |
| 2008 FY | 90.62 Million USD | -24.76% |
| 2008 Q4 | 90.62 Million USD | 3.5% |
| 2008 Q3 | 87.55 Million USD | -9.68% |
| 2008 Q2 | 96.93 Million USD | -7.97% |
| 2008 Q1 | 105.33 Million USD | -12.55% |
| 2007 Q3 | 87.99 Million USD | -10.65% |
| 2007 Q1 | 87.03 Million USD | -15.41% |
| 2007 Q2 | 98.48 Million USD | 13.15% |
| 2007 FY | 120.44 Million USD | 17.07% |
| 2007 Q4 | 120.44 Million USD | 36.88% |
| 2006 Q3 | 75.49 Million USD | -1.47% |
| 2006 Q1 | 73.47 Million USD | -8.27% |
| 2006 FY | 102.89 Million USD | 28.46% |
| 2006 Q4 | 102.89 Million USD | 36.28% |
| 2006 Q2 | 76.62 Million USD | 4.29% |
| 2005 Q2 | 64.33 Million USD | -9.7% |
| 2005 FY | 80.09 Million USD | 8.75% |
| 2005 Q4 | 80.09 Million USD | 41.25% |
| 2005 Q1 | 71.25 Million USD | -3.25% |
| 2005 Q3 | 56.7 Million USD | -11.87% |
| 2004 Q4 | 73.64 Million USD | -6.86% |
| 2004 Q3 | 79.07 Million USD | -2.4% |
| 2004 Q1 | 83.78 Million USD | 165.27% |
| 2004 Q2 | 81.01 Million USD | -3.31% |
| 2004 FY | 73.64 Million USD | 133.17% |
| 2003 FY | 31.58 Million USD | 0.34% |
| 2003 Q4 | 31.58 Million USD | 0.0% |
| 2002 FY | 31.47 Million USD | 108.23% |
| 2001 FY | 15.11 Million USD | -48.91% |
| 2000 FY | 29.59 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | -19.888% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -6.4% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -28.181% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -502.46% |
| bluebird bio, Inc. | 619.16 Million USD | -61.04% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -692.327% |
| Imunon, Inc. | 21.91 Million USD | -4449.196% |
| Editas Medicine, Inc. | 499.15 Million USD | -99.758% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 96.263% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 70.285% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 16.819% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 69.333% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 29.233% |
| Verastem, Inc. | 149.71 Million USD | -565.983% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 98.77% |
| Waters Corporation | 4.62 Billion USD | 78.45% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 98.99% |
| Biogen Inc. | 26.84 Billion USD | 96.286% |
| Nektar Therapeutics | 398.03 Million USD | -150.506% |
| Perrigo Company plc | 10.8 Billion USD | 90.775% |
| Illumina, Inc. | 10.11 Billion USD | 90.139% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -3426.748% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -27.775% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -348.121% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -1417.881% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 85.426% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -503.131% |
| Evolus, Inc. | 188.99 Million USD | -427.57% |
| Adicet Bio, Inc. | 207.29 Million USD | -381.003% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -405.102% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 96.986% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -384.507% |
| FibroGen, Inc. | 423.52 Million USD | -135.426% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 90.736% |
| OPKO Health, Inc. | 2.01 Billion USD | 50.435% |
| Homology Medicines, Inc. | 47.05 Million USD | -2018.911% |
| Geron Corporation | 394.07 Million USD | -153.021% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 73.965% |
| Exelixis, Inc. | 2.94 Billion USD | 66.112% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -170.59% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -545.846% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 23.358% |
| Zoetis Inc. | 14.28 Billion USD | 93.02% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -69.506% |
| Abeona Therapeutics Inc. | 64 Million USD | -1457.914% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 95.613% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -1682.152% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 66.653% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 69.457% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -60.429% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 42.473% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 4.971% |
| Insmed Incorporated | 1.32 Billion USD | 25.021% |
| TG Therapeutics, Inc. | 329.58 Million USD | -202.529% |
| Incyte Corporation | 6.78 Billion USD | 85.298% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 45.659% |